Autopsy report · NCT01383148
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Cause of deathNo reason given
Life of this trial
- Registered 10 months before it started.
- Ran for about 4 years 3 months before it stopped.
- 222 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Transgene
- Sponsor type
- Industry
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- TG4010; placebo
- Participants
- 222
- Sites
- 72
- Countries
- Belgium, France, Germany, Hungary, Israel, Italy, Poland, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.